Fore Pharmas latest report ‘Global Thromboembolism Drug Pipeline Capsule – 2011 is an outline of all the key research and development (R&D) activities of the global thromboembolism drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the thromboembolism drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- Thromboembolism: Overview
- Thromboembolism Drug Pipeline Overview
- Thromboembolism Phase 3 Clinical Trial Drug Pipeline Insights
- Thromboembolism Phase 2 Clinical Trial Drug Pipeline Insights
- Thromboembolism Phase 1 Clinical Trial Drug Pipeline Insights
- Thromboembolism Preclinical Research Drug Pipeline Insights
- Thromboembolism Drug Discovery Pipeline Insights
- Geographic Landscape of Thromboembolism R&D Activities
- Thromboembolism R&D Activities in North America
- Thromboembolism R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Thromboembolism Drug Market

1. Thromboembolism: Disease Definition
2. Thromboembolism Drug Pipeline Overview
3. Thromboembolism Phase 3 Clinical Trial Drug Pipeline Insights
4. Thromboembolism Phase 2 Clinical Trial Drug Pipeline Insights
5. Thromboembolism Phase 1 Clinical Trial Drug Pipeline Insights
6. Thromboembolism Preclinical Research Drug Pipeline Insights
7. Thromboembolism Drug Discovery Pipeline Insights
8. Geographic Landscape of Thromboembolism R&D Activities
8.1 Thromboembolism R&D Activities in North America
8.2 Thromboembolism R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Thromboembolism Drug Market
10 Research Methodology Table 1: Thromboembolism Drug Pipeline: Phase 3 Clinical Trial

Table 2: Thromboembolism Drug Pipeline: Phase 2 Clinical Trial
Table 3: Thromboembolism Drug Pipeline: Phase 1 Molecules
Table 4: Thromboembolism Drug Pipeline: Preclinical Research
Table 5: Thromboembolism R&D Activities by Geography
Table 6: Thromboembolism Drug Pipeline: North America
Table 7: Thromboembolism Drug Pipeline: Europe
Table 8: Thromboembolism Drug Pipeline: Licensing Activities

Figure 1 : Thromboembolism Drug Pipeline Molecules by Stages
Figure 2 : Thromboembolism R&D Activities by Geography